MONTREAL, June 10 /CNW Telbec/ - Aegera Therapeutics Inc. is extremely
pleased to announce the initiation of a Phase 1 clinical trial of the IAP
("Inhibitor of Apoptosis Protein") inhibitor, HGS1029 (formerly AEG40826), as
a monotherapy in patients with advanced solid tumors. This small molecule IAP
inhibitor was developed by Aegera and licensed to Human Genome Sciences, Inc.
(Nasdaq: HGSI) for oncology development in December 2007. As part of this
agreement, Aegera maintains full ownership of all rights to this class of
molecules for the Japanese market and global rights for non-oncology
"We are impressed with the research and development teams that HGS has
applied to the advancement of this exciting collaborative oncology program. In
a very short period of time, their clinical team has advanced this program to
its first clinical trial and we are confident that their pro-active approach
will lead to the rapid and successful development of this potent molecule
across a broad range of cancer indications. In addition, our respective
research teams are working very closely together to continue to build on
Aegera's IAP expertise and to identify additional back-up and best-in-class
compounds to follow the initial lead." commented Dr. Mike Berendt, Aegera
President & CEO.
Aegera also announced today the receipt of its first milestone payment
under this collaboration agreement. The payment, in the amount of
US$5 million, was triggered by the FDA clearance of the Investigational New
Drug (IND) application for HGS1029.
About Aegera Therapeutics Inc.
Aegera Therapeutics is a clinical stage biotechnology company focused on
developing drugs that control apoptosis to address major unmet medical needs.
In addition to HGS1029 (AEG40826), Aegera has three other programs in clinical
- AEG35156 targets the key anti-apoptotic protein XIAP, and is currently
in multiple Phase II human clinical trials for the treatment of solid
tumors and leukemia;
- AEG41174 is a novel, non-ATP competitive, small molecule tyrosine
kinase inhibitor targeting therapeutically significant kinases
including JAK2 and Bcr-Abl, and is currently in Phase I clinical
- AEG33773 is a novel, orally bioavailable small molecule developed to
treat painful diabetic neuropathy and is in Phase I clinical studies.
For further information:
For further information: Donald Olds, MSc, MBA, Chief Operating Officer
& CFO, Aegera Therapeutics Inc., (514) 288-5532 *295, firstname.lastname@example.org